The Post-Traumatic Stress Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Post-Traumatic Stress Disorder Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Post-Traumatic Stress Disorder Market.
Some of the key takeaways from the Post-Traumatic Stress Disorder Pipeline Report:
Companies across the globe are diligently working toward developing novel Post-Traumatic Stress Disorder treatment therapies with a considerable amount of success over the years.
Post-Traumatic Stress Disorder companies working in the treatment market are Lundbeck, Atai Life Sciences, Bionomics Limited, Alto Neuroscienc, Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceuticals, Nobilis Therapeutics, Bionomics, Boehringer Ingelheim, Bionorica SE, H. Lundbeck A/S, and others, are developing therapies for the Post-Traumatic Stress Disorder treatment
Emerging Post-Traumatic Stress Disorder therapies such as – Lu AG06466, EMP-01, BNC210, ALTO-100, ZP150, NYX-783, Brexpiprazole, NBTX-001, BNC 210, BI 1358894, BX-1, Lu AG06466, and others are expected to have a significant impact on the Post-Traumatic Stress Disorder market in the coming years.
In October 2022, Osanetant (ACER-801), a medication for treating acute stress disorder and post-traumatic stress disorder (PTSD), has been given a new indication by Acer Therapeutics Inc
In September 2022, EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative being developed by atai Life Sciences N.V. for the treatment of post-traumatic stress disorder (PTSD) and other indications, has received the regulatory and ethics approvals needed from Medsafe and HDEC, respectively, to begin enrolling participants in the study’s Phase 1
In May 2022, A poster containing information from preclinical tests of Aptinyx’s NYX-783 in PTSD model organisms was displayed at the American Psychiatric Association Annual Meeting, which took place in New Orleans, Louisiana, from May 21 to 25, 2022
In May 2022, A research and development partnership between Beckley Psytech Limited and Lophora ApS was announced. According to the terms of the agreement, Beckley Psytech will collaborate widely on R&D as well as jointly fund the continued development of the Lophora pipeline
Post-Traumatic Stress Disorder Overview
People who have encountered or witnessed a traumatic incident, such as a natural disaster, a catastrophic accident, a terrorist attack, war/combat, or rape, or who have been threatened with death, physical assault, or serious injury, may develop post-traumatic stress disorder (PTSD), a psychiatric disease.
Get a Free Sample PDF Report to know more about Post-Traumatic Stress Disorder Pipeline Therapeutic Assessment-
Emerging Post-Traumatic Stress Disorder Drugs Under Different Phases of Clinical Development Include:
Lu AG06466: Lundbeck
EMP-01: Atai Life Sciences
BNC210: Bionomics Limited
Brexpiprazole: Otsuka Pharmaceutical Development & Commercialization
ALTO-100: Alto Neuroscienc
NBTX-001 Xenon Inhaler: Nobilis Therapeutics
ZP150: Jazz Pharmaceuticals
Brexpiprazole: Otsuka Pharmaceuticals
NBTX-001: Nobilis Therapeutics
BNC 210: Bionomics
BI 1358894: Boehringer Ingelheim
BX-1: Bionorica SE
Lu AG06466: H. Lundbeck A/S
Route of Administration
Post-Traumatic Stress Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Products have been categorized under various Molecule types, such as
Post-Traumatic Stress Disorder Pipeline Therapeutics Assessment
Post-Traumatic Stress Disorder Assessment by Product Type
Post-Traumatic Stress Disorder By Stage and Product Type
Post-Traumatic Stress Disorder Assessment by Route of Administration
Post-Traumatic Stress Disorder By Stage and Route of Administration
Post-Traumatic Stress Disorder Assessment by Molecule Type
Post-Traumatic Stress Disorder by Stage and Molecule Type
DelveInsight’s Post-Traumatic Stress Disorder Report covers around 25+ products under different phases of clinical development like-
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Post-Traumatic Stress Disorder product details are provided in the report. Download the Post-Traumatic Stress Disorder pipeline report to learn more about the emerging Post-Traumatic Stress Disorder therapies
Some of the key companies in the Post-Traumatic Stress Disorder Therapeutics Market include:
Key companies developing therapies for Post-Traumatic Stress Disorder are – ptinyx, Nobilis Therapeutics Inc., Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, Otsuka Pharmaceutical Development & Commercialization, Inc., Halucenex Life Sciences, Bionorica SE, MAPS Europe B.V., Hoffmann-La Roche, Praxis Precision Medicines, Alto Neuroscience, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Psy Therapeutics Inc, Chronos Therapeutics, Mydecine Innovations Group, ATAI LIFE SCIENCES N.V., Acer Therapeutics, Alzamend Neuro, Inc., Innovation1 Biotech Inc., Lophora, Virpax Pharmaceuticals, Alto Neuroscience, VistaGen, ANANDA Scientific, Bright Minds Biosciences, and others.
Post-Traumatic Stress Disorder Pipeline Analysis:
The Post-Traumatic Stress Disorder pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Post-Traumatic Stress Disorder with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Post-Traumatic Stress Disorder Treatment.
Post-Traumatic Stress Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Post-Traumatic Stress Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Post-Traumatic Stress Disorder market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Post-Traumatic Stress Disorder drugs and therapies
Post-Traumatic Stress Disorder Pipeline Market Drivers
Increase in prevalence, increased initiatives to create public awareness and knowledge of disease are some of the important factors that are fueling the Post-Traumatic Stress Disorder Market.
Post-Traumatic Stress Disorder Pipeline Market Barriers
However, heterogeneity of the symptoms, delayed-onset PTSD and other factors are creating obstacles in the Post-Traumatic Stress Disorder Market growth.
Scope of Post-Traumatic Stress Disorder Pipeline Drug Insight
Key Post-Traumatic Stress Disorder Companies: Lundbeck, Atai Life Sciences, Bionomics Limited, Alto Neuroscienc, Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceuticals, Nobilis Therapeutics, Bionomics, Boehringer Ingelheim, Bionorica SE, H. Lundbeck A/S, and others
Key Post-Traumatic Stress Disorder Therapies: Lu AG06466, EMP-01, BNC210, ALTO-100, ZP150, NYX-783, Brexpiprazole, NBTX-001, BNC 210, BI 1358894, BX-1, Lu AG06466, and others
Post-Traumatic Stress Disorder Therapeutic Assessment: Post-Traumatic Stress Disorder current marketed and Post-Traumatic Stress Disorder emerging therapies
Post-Traumatic Stress Disorder Market Dynamics: Post-Traumatic Stress Disorder market drivers and Post-Traumatic Stress Disorder market barriers
Request for Sample PDF Report for Post-Traumatic Stress Disorder Pipeline Assessment and clinical trials
Table of Contents
Post-Traumatic Stress Disorder Report Introduction
Post-Traumatic Stress Disorder Executive Summary
Post-Traumatic Stress Disorder Overview
Post-Traumatic Stress Disorder- Analytical Perspective In-depth Commercial Assessment
Post-Traumatic Stress Disorder Pipeline Therapeutics
Post-Traumatic Stress Disorder Late Stage Products (Phase II/III)
Post-Traumatic Stress Disorder Mid Stage Products (Phase II)
Post-Traumatic Stress Disorder Early Stage Products (Phase I)
Post-Traumatic Stress Disorder Preclinical Stage Products
Post-Traumatic Stress Disorder Therapeutics Assessment
Post-Traumatic Stress Disorder Inactive Products
Company-University Collaborations (Licensing/Partnering) Analysis
Post-Traumatic Stress Disorder Key Companies
Post-Traumatic Stress Disorder Key Products
Post-Traumatic Stress Disorder Unmet Needs
Post-Traumatic Stress Disorder Market Drivers and Barriers
Post-Traumatic Stress Disorder Future Perspectives and Conclusion
Post-Traumatic Stress Disorder Analyst Views
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Address:27 Drydock Ave S. Jones Blvd #2432
Country: United States